BlueClinical

What BlueClinical does

BlueClinical (legally Blueclinical, Ltd) is a privately owned, independent full-service Contract Research Organization (CRO) headquartered in Matosinhos, Portugal. The company specializes in bioequivalence and early-stage clinical research, offering a unified portfolio of services including Bioequivalence and Phase I Studies in healthy subjects and patients, Translational Medicine Consultancy, and Site Management. Its customer base is horizontal, serving pharmaceutical and biotechnology companies that require specialized expertise in early-stage clinical studies, regulatory compliance, and accelerated time-to-market for drug development. The company markets itself as part of the Astrum company network (AstrumCRO) with 25 years of combined clinical excellence across the network.

BlueClinical operates as a professional services business on a project-based/contract model, with services quoted based on scope, duration, and complexity. Pricing is not publicly disclosed, consistent with B2B CRO norms. Customer acquisition is sales-led through direct outreach to pharma and biotech, supplemented by referrals, conference participation, and an active digital presence via website, LinkedIn, Facebook, and a newsletter subscription channel. The firm targets both healthy volunteer and patient populations for its trials, with a Portuguese and broader European geographic scope. The company has 101-250 employees and is structured as a Portuguese private limited company (Blueclinical, Ltd) operating under Astrum as its strategic operating parent.

The technology footprint is operational rather than platform-led: core capabilities center on clinical research execution, regulatory compliance with European (EMA) and Portuguese frameworks, and site management. No APIs, software products, AI/ML capabilities, or proprietary technology platforms are disclosed. The firm maintains a single headquarters in Matosinhos with limited publicly disclosed geographic footprint beyond Portugal, and engagement is anchored in the Astrum network affiliation rather than independent international scaling.

Name

BlueClinical

Legal name

Blueclinical, Ltd

Website

https://blueclinical.pt

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

BlueClinical is a privately owned, independent full-service CRO based in Matosinhos, Portugal, specializing in bioequivalence and Phase I clinical studies, translational medicine consultancy, and site management for pharmaceutical and biotechnology clients. It operates as part of the Astrum company network.

Ownership category

akta.pro rank

Product category

Clinical Research Services (CRO)

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAGAAAA

Clinical CROs (Phase I–IV)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAAAB

Preclinical CROs (Discovery/Pharmacology/DMPK)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

Keywords

• Clinical research services
• Bioequivalence studies
• Phase I trials
• Translational medicine
• Site management services

Headquarters

HQ city

Matosinhos

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Research Services: BlueClinical generates revenue through providing full-service CRO services including bioequivalence studies, Phase I clinical studies in healthy subjects and patients, translational medicine consultancy, and site management services. As a contract research organization, the company likely operates on a project-based/contract model with pharmaceutical and biotech clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

BlueClinical is a privately owned independent full-service Contract Research Organization (CRO) that delivers highly-customized and fully-compliant bioequivalence and Phase I clinical study services in healthy subjects and patients. The company complements these core trial services with translational medicine consultancy bridging preclinical and clinical development, and site management services for clinical trial operations. Operating as part of the Astrum company (AstrumCRO) network with 25 years of combined clinical excellence.

Product overview

BlueClinical is a privately owned independent full-service CRO offering a unified portfolio of clinical research services centered on bioequivalence and early-stage clinical studies. The core services include Bioequivalence and Phase I Studies, Translational Medicine Consultancy, and Site Management. All services are designed for healthy subjects and patient populations, with an emphasis on regulatory compliance and accelerated time-to-market for clients.

Differentiator

Problem solved

Functional benefit

Products and services

• Bioequivalence and Phase I Studies Highly-customized and fully-compliant bioequivalence and Phase I clinical study services in healthy subjects and patients, designed to maximize client competitiveness and time-to-market for drug development programs.
• Translational Medicine Consultancy Expert consultancy services bridging preclinical and clinical development to support translation of drug candidates and inform early-stage clinical strategy.
• Site Management Site management services for clinical trial operations supporting the execution of early-stage clinical studies in healthy subjects and patient populations.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• AstrumcoreStrategic or Co-development PartnerBlueClinical is part of the Astrum company (AstrumCRO). This partnership provides access to 25 years of combined clinical excellence. The relationship allows BlueClinical to leverage the broader Astrum network resources and expertise in clinical research operations.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• PAREXEL International: PAREXEL is a long-established global CRO offering full-service clinical development including early-phase; broad incumbent competitor for BlueClinical on Phase I trials and bioequivalence studies.
• Labcorp Drug Development (Fortrea): Fortrea (spun out from Labcorp Drug Development) and Labcorp's central laboratory business include early-phase and bioequivalence services; broad incumbents that overlap with BlueClinical's clinical trial testing and Phase I capabilities.
• IQVIA: IQVIA is the world's largest CRO with comprehensive early-phase clinical research capabilities; competes with BlueClinical on Phase I and bioequivalence projects as part of a much wider clinical and commercial services portfolio.
• ICON plc: ICON plc is one of the largest global CROs offering Phase I through post-approval services; a broad incumbent competing with BlueClinical on early-phase trials while offering scale and global reach that BlueClinical cannot match.
• Charles River Laboratories: Charles River Laboratories is a large, established CRO/CDMO with broad early-phase and preclinical services including bioequivalence; competes with BlueClinical for early-phase work while serving a much wider portfolio of therapeutic and service categories.
• PRA Health Sciences (now part of ICON): PRA Health Sciences, now operating under ICON, is a major global CRO with strong early-phase clinical trial offerings; a broad incumbent competitor for BlueClinical's targeted Phase I work.

Direct peers

• Quotient Sciences: Quotient Sciences is a UK-based CRO specializing in early-phase clinical pharmacology, formulation development, and bioequivalence studies — directly overlapping BlueClinical's Phase I and bioequivalence focus with similar customer segments (pharma and biotech sponsors).
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized global CRO with strong early-phase and bioequivalence expertise, comparable in scale and customer base to BlueClinical and competing for similar Phase I and translational medicine projects.
• SGS Health Sciences: SGS Health Sciences is a global CRO with significant Phase I clinical research and bioequivalence capabilities, particularly in Europe, serving pharma and biotech clients — a direct competitor in BlueClinical's core service offering and geography.
• Ergomed plc: Ergomed is a UK/European mid-sized CRO with Phase I and clinical research services to pharma and biotech — comparable in scale, geography, and customer base to BlueClinical.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Blueclinical
• LinkedInlinkedin.com/company/blueclinical

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BlueClinical